2008
Voluntary oral nicotine intake in mice down-regulates GluR2 but does not modulate depression-like behaviors
Vieyra-Reyes P, Picciotto MR, Mineur YS. Voluntary oral nicotine intake in mice down-regulates GluR2 but does not modulate depression-like behaviors. Neuroscience Letters 2008, 434: 18-22. PMID: 18261852, PMCID: PMC2757003, DOI: 10.1016/j.neulet.2008.01.021.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnimalsAnxiety DisordersBehavior, AnimalBrainCyclic AMP Response Element-Binding ProteinDepressive DisorderDown-RegulationGlutamic AcidMaleMiceMice, Inbred BALB CMice, Inbred C57BLMotor ActivityNeural PathwaysNicotineNicotinic AgonistsNucleus AccumbensReceptors, AMPARewardSynaptic TransmissionTobacco Use DisorderVentral Tegmental AreaVolitionConceptsCAMP response element-binding proteinDepression-like behaviorVentral tegmental areaNucleus accumbensMesolimbic systemNicotine preferenceChronic nicotine exposureDepression-related behaviorsNon-treated animalsBALB/cOral nicotine intakeCentral nervous systemResponse element-binding proteinNicotine exposureNicotine rewardMesolimbic dopamine projectionsTegmental areaNicotine intakeGlutamate receptorsDopamine projectionsElement-binding proteinNervous systemLocomotor activityMice C57BL/6JGluR1 levels
2006
Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?
Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS & Neurological Disorders - Drug Targets 2006, 5: 225-32. PMID: 16611095, DOI: 10.2174/187152706776359600.Peer-Reviewed Original ResearchConceptsStress-related neural pathwaysBrain stress pathwaysSerotonin-producing neuronsDistribution of galaninDepression-related behaviorsDorsal raphe nucleusExpression of galaninAdministration of galaninNovel therapeutic targetDrug addictionPotential roleAnxiety-like responsesGalanin agonistsGalanin systemRaphe nucleusDopamine neuronsOpiate withdrawalLocus coeruleusNeuronal typesRodent modelsCurrent evidenceGalaninPsychiatric disordersTherapeutic targetOpiate reinforcement